Obesity hypertension is related more to insulin's fatty acid than glucose action

Hypertension

Volumn 27, Issue 3 II, 1996, Pages 723-728

  Egan, Brent M ^a   Hennes, Magda M I ^b   Stepniakowski, Konrad T ^a   O'Shaughnessy, Irene M ^b   Kissebah, Ahmed H ^b   Goodfriend, Theodore L ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

fatty acids, nonesterified; glucose; insulin; obesity

Indexed keywords

FATTY ACID; GLUCOSE; INSULIN; TRIACYLGLYCEROL LIPASE;

ADULT; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; MALE; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0029868570     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.27.3.723     Document Type: Conference Paper

References (41)

1. Stern M, Haffner S. Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis. 1986;6:123-129.
2. Rocchini AP, Katch V, Kveselis D, Moorehead C, Martin M, Lampman R, Gregory M. Insulin and renal sodium retention in obese adolescents. Hypertension. 1989;14:367-374.
3. Lind L, Lithell H, Pollare T. Is it hyperinsulinemia or insulin resistance that is related to hypertension and other metabolic cardiovascular risk factors? J Hypertens. 1993;11(suppl 4):S11-S16.
4. Baron AD, Brechtel-Hook G, Johnson A, Hardin D. Skeletal muscle blood flow: a possible link between insulin resistance and blood pressure. Hypertension. 1993;21:129-135.
5. Muller DC, Elahi D, Pratley RE, Tobin JD, Andres R. An epidemiological test of the hyperinsulinemia-hypertension hypothesis. J Clin Endocrinol Metab. 1991;76:544-548.
6. Hall JE, Coleman TG, Mizelle HL. Does chronic hyperinsulinemia cause hypertension? Am J Hypertens. 1989;2:171-173.
7. Hall JE, Brands MW, Kivlighn SD, Mizelle HL, Hildebrandt DA, Gaillard CA. Chronic hyperinsulinemia and blood pressure: interaction with catecholamines? Hypertension. 1990;15:519-527.
8. Anderson EA, Balon TW, Hoffman RP, Sinkey CA, Mark AL. Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. J Clin Invest. 1992;87: 2247-2252.
9. Neahring JM, Stepniakowski K, Greene AS, Egan BM. Insulin does not reduce forearm α-vasoreactivity in obese hypertensive or lean normotensive men. Hypertension. 1993;22:584-590.
10. Egan BM, Stepniakowski K, Nazzaro P. Insulin levels are similar in obese salt-sensitive and salt-resistant hypertensive subjects. Hypertension. 1994;23(suppl I):I-1-I-7.
11. Reaven GM, Hollenbeck C, Jeng C-Y, Wu MS, Chen Y-DI. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes. 1988;37:1020-1024.
12. Golay A, Swislocki ALM, Chen Y-DI, Jaspan JB, Reaven GM. Effect of obesity on ambient plasma glucose, free fatty acid, insulin, growth hormone, and glucagon concentrations. J Clin Endocrinol Metab. 1986;63:481-484.
13. Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles JM. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest. 1989;83:1168-1173.
14. Cabezas MC, de Bruin TWA, de Valk HW, Shoulder CC, Jansen H, Erkelens DW. Impaired fatty acid metabolism in familial combined hyperlipidemia: a mechanism associating hepatic apolipoprotuin B overproduction and insulin resistance. J Clin Invest. 1993;92:160-168.
15. Grekin RJ, Vollmer AP, Sider RS. Pressor effects of portal venous oleate infusion: a proposed mechanism for obesity hypertension. Hypertension. 1995;26:193-198.
16. Stepniakowski KT, Egan BM. Additive effects of hypertension and obesity to limit venous distensibility. Am J Physiol. 1995;268: R562-R568.
17. Stepniakowski KT, Goodfriend TL, Egan BM. Fatty acids enhance vascular α-adrenergic sensitivity. Hypertension. 1995;25(part 2):II-774-11-778.
18. Davda RK, Stepniakowski KT, Lu G, Ullian ME, Goodfriend TL, Egan BM. Oleic acid inhibits endothelial cell nitric oxide synthase by a PKC-independent mechanism. Hypertension. 1995;26:764-770.
19. Roust LR, Jensen MD. Postprandial free fatty acid kinetics are abnormal in upper body obesity. Diabetes. 1993;42:1567-1573.
20. Chen Y-DI, Golay A, Swislocki ALM, Reaven GM. Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1987;64:17-21.
21. O'Shaughnessy IM, Myers TM, Stepniakowski K, Nazzaro P, Kelly TM, Hoffman RG, Egan BM, Kissebah AH. Glucose metabolism in obese hypertensives and normotensives. Hypertension. 1995;26: 186-192.
22. Hennes MM, O'Shaughnessy IM, Egan BM, Kissebah AH. Angiotensin converting enzyme inhibition and improvement of insulin's antilipolytic action in abdominally obese hypertensives. J Invest Med. 1995;43:239. Abstract.
23. Goodfriend TL, Egan B, Stepniakowski K, Ball DL. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension. 1995;25:30-36.
24. Bonora E, Moghetti P, Zancanara C, Cigolini M, Querena M, Cacciatori V, Aorgnati C, Muggeo M. Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab. 1989;68:374-378.
25. Egan BM. Neurohumoral, hemodynamic, and microvascular changes as mechanisms of insulin resistance in hypertension: a provocative but partial picture. Int J Obes. 1991;15:133-139.
26. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO. Reflex sympathetic activation induces insulin resistance in the human forearm. Hypertension. 1993;21:618-623.
27. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868-873.
28. Ferrannini E, Buzzigoli G, Bonadonna R, Guiorico MA, Leggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350-357.
29. Istfan NW, Plaisted CS, Bistrian BR, Blackburn GL. Insulin resistance versus insulin secretion in the hypertension of obesity. Hypertension. 1992;19:385-392.
30. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic activation and vasodilation in normal humans. J Clin Invest. 1991;87:2246-2252.
31. Nazzaro P, Stepniakowski K, O'Shaughnessy IM, Kissebah AH, Egan BM. Elevated blood pressures in obese young men with mild hypertension are sustained during the day and night. Am J Hypertens. 1994;7:609-614.
32. Bülow J, Madsen J, Hojgaard L. Reversibility of the effects on local circulation of high lipid concentrations in blood. Scand J Clin Lab Invest. 1990;50:291-296.
33. Williams RR, Hunt SC, Hopkins PN, Stults BM, Wu LL, Hasstedt SJ, Barlow GK, Stevenson SH, Lalouel JM, Kuida H. Familial dyslipidemic hypertension. JAMA. 1988;259:3579-3586.
34. Egan B, Panis R, Hinderliter A, Schork N, Julius S. Mechanism of increased α-adrenergic vasoconstriction in human essential hypertension. J Clin Invest. 1987;80:812-817.
35. Rao GN, Alexander RW, Runge MS. Linoleic acid and its metabolites, hydroperoxy-octadecadienoic acids, stimulate c-fos, c-jun, and c-myc mRNA expression, mitogen-activated protein kinase activation, and growth in rat aortic smooth muscle cells. J Clin Invest. 1995;96:842-847.
36. Ordway RW, Singer JJ, Walsh JV. Direct regulation of ion channels by fatty acids. Trends Neurosci. 1991;14:96-100.
37. Vesell ES, Chambers CE, Passananti T, Demers LM, Beyer KH. Effects of pyrazinoylguanidine on the glucose-fatty acid cycle innormal subjects and patients with non-insulin dependent diabetes mellitus. J Clin Pharmacol 1993;33:823-831.
38. Beyer KH, Gelarden RT, Vary JE, Brown LE, Vesell ES. Novel multivalent effects of pyrazinoylguanidine in patients with azotemia. Clin Pharmacol Ther. 1990;47:629-638.
39. Chambers CE, Vesell ES, Helm C, Passananti GT, Beyer KH. Pyrazinoylguanidine: antihypertensive, hypocholesterolemic, and renin effects. J Clin Pharmacol. 1992;32:1128-1134.
40. Stout RW. Insulin and atheroma: an update. Lancet. 1987;1: 1077-1079.
41. Khan WA, Blobe G, Halpern A, Taylor W, Wetsel WC, Burns D, Loomis C, Hannun YA. Selective regulation of protein kinase C isoenzymes by oleic acid in human platelets. J Biol Chem. 1993;268: 5063-5068.